Results 141 to 150 of about 20,678 (258)

Waist‐to‐height ratio and renal dysfunction as independent correlates of low handgrip strength in patients with type 2 diabetes

Journal of Diabetes Investigation, EarlyView.
In 1,468 patients with type 2 diabetes, central obesity (WHtR >0.5) neutralizes the protective effects of higher BMI on muscle strength. Concurrently, visceral adiposity and CKD impose an additive threat, maximizing low handgrip strength risk (aOR = 1.74). Combining WHtR and renal tracking optimizes clinical sarcopenia screening.
Shing‐Hua Chen, Chen‐Kai Chou, Shao‐Wen Weng, Jung‐Fu Chen, Feng‐Chih Shen   +4 more
wiley   +1 more source

Risk of lower extremity complications with GLP-1 receptor agonists, SGLT2 inhibitors, and DPP-4 inhibitors in peripheral artery disease. [PDF]

Diabetes Res Clin Pract
Hong AT, Lin F, Luu IY, Shin L, Han SM, Armstrong DG, Tan TW.   +6 more
europepmc   +1 more source

Clinical characteristics of Sarcopenic obesity in Japanese people with type 2 diabetes: A post hoc analysis of the sub‐cohort iDIAMOND study

Journal of Diabetes Investigation, EarlyView.
Among participants aged 40–75 years, sarcopenic obesity was observed in 4.9% of those with T2D and 0.5% of non‐D individuals. Sarcopenic obesity is more prevalent in individuals with T2D and is associated with impaired physical QOL, reduced walking ability, and increased falls.
Hiroyasu Mori, Kasei Ko, Satoko Notomi, Sumiko Yoshida, Tetsuyuki Yasuda, Yutaka Umayahara, Sayoko Shimizu, Kayoko Ryomoto, Kazutomi Yoshiuchi, Saeko Osawa, Tsunehiko Yamamoto, Akio Kuroda, Munehide Matsuhisa   +12 more
wiley   +1 more source

Gastric Neoplasm Risk with DPP-4 Inhibitors, GLP-1 Receptor Agonists, and SGLT2 Inhibitors: Network Meta-Analysis of Randomized Trials. [PDF]

Int J Mol Sci
Hung CM, Hsu CW, Zeng BS, Suen MW, Chen JJ, Zeng BY, Carvalho AF, Stubbs B, Chen YW, Chen TY, Hsu SP, Wang HY, Liang CS, Tu YK, Tseng PT.   +14 more
europepmc   +1 more source

USP30 inhibits wound healing in diabetic foot ulcers by promoting TRAF6‐induced ferroptosis and angiogenesis inhibition

Journal of Diabetes Investigation, EarlyView.
High glucose upregulates USP30 in HUVECs, which deubiquitinates and stabilizes TRAF6. Stabilized TRAF6 suppresses GPX4 and SLC7A11, increases ROS/MDA/lipid peroxidation, and activates ferroptosis and apoptosis, leading to impaired angiogenesis and delayed wound healing.
Jingjing Yuan, Shuang Sui, Zhenghua Yang, Kaiwen Zhang, Qiang Hu   +4 more
wiley   +1 more source

NeSyDPP-4: discovering DPP-4 inhibitors for diabetes treatment with a neuro-symbolic AI approach. [PDF]

Front Bioinform
Hossain D, Saghapour E, Chen JY.
europepmc   +1 more source

Cardiovascular preventive role of thiazolidinedione in patients with type 2 diabetes mellitus undergoing percutaneous coronary intervention

Journal of Diabetes Investigation, EarlyView.
Among patients with type 2 diabetes undergoing percutaneous coronary intervention, thiazolidinedione use was independently associated with a significantly reduced risk of a composite of myocardial infarction, stroke, and all‐cause death, notably without an increased risk of admission for heart failure. ABSTRACT Background Thiazolidinediones (TZD) are a
Jinkwon Kim, Jimin Jeon, Joonsang Yoo, Minyoul Baik, Seok‐Jae Heo, Ji Woong Roh   +5 more
wiley   +1 more source

Agent-specific, histopathology-stratified hematologic malignancy risk among dpp-4 inhibitors, glp-1 receptor agonists, and SGLT2 inhibitors: a network meta-analysis of 270,471 participants. [PDF]

J Hematol Oncol
Lin PY, Zeng BS, Chen JJ, Zeng BY, Suen MW, Hung CM, Hsu CW, Stubbs B, Chen YW, Chen TY, Lei WT, Hsu SP, Shiue YL, Su KP, Li CT, Wang HY, Tseng PT, Liang CS.   +17 more
europepmc   +1 more source

Sodium zirconium cyclosilicate compared with potassium restriction for hyperkalemia management in type 2 diabetes: The SILVERSTAR trial

Journal of Diabetes Investigation, EarlyView.
ABSTRACT Aims/Introduction To demonstrate noninferiority of continued sodium zirconium cyclosilicate therapy versus a potassium‐restricted diet in achieving normokalemia at Visit 7 (Days 28–42) in individuals with type 2 diabetes and hyperkalemia, using a noninferiority margin of −10 percentage points (one‐sided α = 0.025).
Masahide Hamaguchi, Junya Hironaka, Hiroshi Okada, Mari Yoneda, Ayaka Kobayashi, Yoshitaka Hashimoto, Aya Kitae, Noriyuki Kitagawa, Akio Kishi, Michiyo Ishii, Mai Asano, Masahiro Yamazaki, Toru Tanaka, Hanako Nakajima, Eiko Sato, Michiaki Fukui   +15 more
wiley   +1 more source

Comparative Efficacy, Safety, and Cost-Utility of DPP-4 Inhibitors and Metformin Combination Therapy in Type 2 Diabetes: A Systematic Review of Real-World Clinical and Economic Outcomes. [PDF]

J Diabetes Res
Jimoh AO, Hudu SA, Sabir AA, Adamu AA, Bello N, Tahir A, Abubakar N.   +6 more
europepmc   +1 more source